>
Switch to:

Cellectar Biosciences Price-to-Tangible-Book

: 1.43 (As of Today)
View and export this data going back to 2005. Start your Free Trial

As of today (2021-10-17), Cellectar Biosciences's share price is $0.9171. Cellectar Biosciences's Tangible Book per Share of Jun. 2021 for the quarter that ended in Jun. 2021 was $0.64. Hence, Cellectar Biosciences's Price to Tangible Book Ratio of today is 1.43.

The historical rank and industry rank for Cellectar Biosciences's Price-to-Tangible-Book or its related term are showing as below:

NAS:CLRB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.68   Med: 3.45   Max: 849.6
Current: 1.43

0.68
849.6

During the past 13 years, Cellectar Biosciences's highest Price to Tangible Book Ratio was 849.60. The lowest was 0.68. And the median was 3.45.

NAS:CLRB's Price-to-Tangible-Book is ranked lower than
99.99% of the 250 Companies
in the Biotechnology industry.

( Industry Median: 4.88 vs. NAS:CLRB: 1.43 )

A closely related ratio is called PB Ratio. As of today, Cellectar Biosciences's share price is $0.9171. Cellectar Biosciences's Book Value per Sharefor the quarter that ended in Jun. 2021 was $0.64. Hence, Cellectar Biosciences's P/B Ratio of today is 1.43.


Cellectar Biosciences Price-to-Tangible-Book Historical Data

The historical data trend for Cellectar Biosciences's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Price-to-Tangible-Book
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 2.82 0.68 2.67 2.72

Cellectar Biosciences Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Price-to-Tangible-Book Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.73 2.21 2.72 2.23 1.86

Competitive Comparison

For the Biotechnology subindustry, Cellectar Biosciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Cellectar Biosciences Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Price-to-Tangible-Book falls into.



Cellectar Biosciences Price-to-Tangible-Book Calculation

Cellectar Biosciences's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Jun. 2021 )
=0.9171/0.64
=1.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Cellectar Biosciences Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences Business Description

Cellectar Biosciences logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.
Executives
Friend John E. Ii officer: VP, Chief Medical Officer 26 ORCHARD LANE COLT NECK NJ 07722
Swirsky Douglas J director C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD SUITE 455 ROCKVILLE MD 20850
Neis John director 505 S. ROSA ROAD, SUITE 201 MADISON WI 53719
Hill Stephen A director 50 AVENUE GENERAL DE GAULLE BRUXELLES C9 9999999999
Driscoll Frederick W director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DRISCOLL FREDERICK W a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Loren Stefan director 3226 AVENIDA DE SUENO CARLSBAD CA 92009
Elefant Dov officer: Chief Financial Officer EPICEPT CORPORATION 270 SYLVAN AVENUE ENGLEWOOD CLIFFS NJ 07632
Caruso James V director, officer: President and CEO C/O CELLECTAR BIOSCIENCES, INC. 8383 GREENWAY BLVD STE 600 MIDDLETON WI 53562
Longcor Jarrod officer: Chief Business Officer C/O RIB-X PHARMACEUTICALS, INC. 300 GEORGE STREET, SUITE 301 NEW HAVEN CT 06511
Grachev Igor D officer: Chief Medical Officer 15 REID LANE MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD MALVERN PA 19355
Posner Brian M officer: Chief Financial Officer 1590 REED ROAD PENNINGTON NJ 08534
Hamill John P. officer: Interim CFO 4092 NEW HOPE ROAD FURLONG PA 18925
Kolean Chad J officer: VP, Chief Financial Officer C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON WI 53716
Hertzberg Richard other: significant owner 1329 STRATFORD COURT DEL MAR CA 92014

Cellectar Biosciences Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)